GSA Capital Partners LLP Acquires New Shares in HilleVax, Inc. (NASDAQ:HLVX)

GSA Capital Partners LLP bought a new position in HilleVax, Inc. (NASDAQ:HLVX) in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 71,463 shares of the company’s stock, valued at approximately $126,000. GSA Capital Partners LLP owned about 0.14% of HilleVax as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also bought and sold shares of the stock. Tidal Investments LLC bought a new stake in shares of HilleVax in the first quarter worth $207,000. Maven Securities LTD purchased a new stake in shares of HilleVax during the 2nd quarter valued at about $217,000. Algert Global LLC bought a new position in shares of HilleVax in the 2nd quarter worth approximately $519,000. Rhumbline Advisers boosted its holdings in shares of HilleVax by 27.0% in the second quarter. Rhumbline Advisers now owns 42,658 shares of the company’s stock worth $617,000 after buying an additional 9,073 shares during the last quarter. Finally, TD Asset Management Inc grew its position in HilleVax by 53.9% during the second quarter. TD Asset Management Inc now owns 54,236 shares of the company’s stock valued at $784,000 after buying an additional 19,000 shares during the period. Institutional investors own 86.42% of the company’s stock.

HilleVax Price Performance

Shares of NASDAQ:HLVX opened at $1.94 on Tuesday. The company has a market capitalization of $96.63 million, a P/E ratio of -0.63 and a beta of 0.78. HilleVax, Inc. has a 1-year low of $1.55 and a 1-year high of $20.22. The firm’s 50 day simple moving average is $1.83 and its two-hundred day simple moving average is $5.26.

HilleVax (NASDAQ:HLVX) last released its earnings results on Thursday, November 7th. The company reported ($0.52) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.10). On average, sell-side analysts anticipate that HilleVax, Inc. will post -2.64 earnings per share for the current fiscal year.

Analyst Ratings Changes

Separately, HC Wainwright reiterated a “neutral” rating and set a $2.00 price target on shares of HilleVax in a research note on Monday, August 12th. Six investment analysts have rated the stock with a hold rating, According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $3.00.

HilleVax Company Profile

HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc and changed its name to HilleVax, Inc in February 2021.